TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14616791

Group type: EXPERIMENTAL
Intervention: ALM mixed with low dose of BCG
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: History of CL and positive LST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALM + BCG
Number of subjects: 0
Study: 10810001

Group type: EXPERIMENTAL
Intervention: Lipase inhibitor
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9299808

Group type: EXPERIMENTAL
Intervention: Panic Appraisal Inventory (PAI)
Number of subjects: 47
Study: 8345434

Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol administered by nebulizer
Number of subjects: 33

Group type: COMPARATOR
Intervention: Aerosolized albuterol administered by MDI-spacer
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Heart rate in nebulizer group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Heart rate in MDI-spacer group
Number of subjects: 33
Study: 3734027

Group type: EXPERIMENTAL
Intervention: Hospice care
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 30114458

Group type: EXPERIMENTAL
Intervention: Behavioral nutrition intervention
Number of subjects: 136
Study: 26755098

Group type: EXPERIMENTAL
Intervention: Timothy grass SLIT tablet (2800 bioequivalent allergen unit)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ragweed SLIT tablet (12 Ambrosia artemisiifolia 1-U) and grass SLIT tablet
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Simultaneous intake of grass and ragweed SLIT tablets
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Timothy grass SLIT tablet
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ragweed SLIT tablet and grass SLIT tablet
Number of subjects: 102
Study: 23952552

Group type: EXPERIMENTAL
Intervention: Severely obese group (BMI ≥ 35 kg/m2)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Non-severely obese group (BMI < 35 kg/m2)
Number of subjects: 1060
Study: 23100508

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 20 mg three times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21095309

Group type: EXPERIMENTAL
Intervention: Glue or patch or buttressing
Number of subjects: 1335

Group type: COMPARATOR
Intervention: Control (single or continuous running sutures or staples)
Number of subjects: 1335
Study: 18839047

Group type: EXPERIMENTAL
Intervention: Increased physical education classes (4 classes, 180 min/week) for girls
Number of subjects: 243

Group type: COMPARATOR
Intervention: Usual physical activity curriculum (90 min/week) for boys
Number of subjects: 243
Study: 16893663

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound scan
Number of subjects: 12639

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 12639
Study: 12865592

Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg/day) + norethisterone acetate (1 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.05 mg) + norethisterone acetate (0.25 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no HRT or other treatments)
Number of subjects: 42
Study: 12201921

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microg kg(‐1) IV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (1 mg kg(‐1), IM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol (1.5 mg kg(‐1))
Number of subjects: 60
Study: 10356140

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 8556566

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms b.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms q.i.d.)
Number of subjects: 20
Study: 1958987

Group type: EXPERIMENTAL
Intervention: 111In-labelled M8
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 111In-labelled 77-1
Number of subjects: 30
Study: 7040695

Group type: EXPERIMENTAL
Intervention: 5% solution of sodium benzyl penicillin
Number of subjects: 260

Group type: COMPARATOR
Intervention: 0.9% NaCl (saline)
Number of subjects: 260
Study: 3908132

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day for 3 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29027510

Group type: EXPERIMENTAL
Intervention: Topical hydroquinone (HQ) 2% applied once nightly for three months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intradermal tranexamic acid (TA) injections administered monthly for three months
Number of subjects: 37
Study: 27209504

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiation therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sequential chemoradiation therapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both treatment sequences
Number of subjects: 102
Study: 25684611

Group type: EXPERIMENTAL
Intervention: Game+Therapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Therapy Only
Number of subjects: 101

Group type: COMPARATOR
Intervention: Game Only
Number of subjects: 101

Group type: COMPARATOR
Intervention: No Game+No Therapy
Number of subjects: 101
Study: 23730730

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 20092954

Group type: EXPERIMENTAL
Intervention: Computer smoking self-report survey
Number of subjects: 575

Group type: COMPARATOR
Intervention: Paper smoking self-report survey
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Computer alcohol use self-report survey
Number of subjects: 575

Group type: COMPARATOR
Intervention: Paper alcohol use self-report survey
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: All groups (C-C, C-P, P-C, P-P)
Number of subjects: 575
Study: 19180887

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MMF withdrawal group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Triple therapy group
Number of subjects: 45
Study: 16376977

Group type: EXPERIMENTAL
Intervention: Intervention group (health care providers delivered sun protection advice and materials)
Number of subjects: 728

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 728

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 728
Study: 12673809

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 59
Study: 11584877

Group type: EXPERIMENTAL
Intervention: Positive aging stereotypes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative aging stereotypes
Number of subjects: 0
Study: 9175047

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 72

Group type: COMPARATOR
Intervention: Captopril and Enalapril
Number of subjects: 72
Study: 7903214

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg alone
Number of subjects: 2706

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg plus diuretic
Number of subjects: 2706

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg plus diuretic and dihydralazine
Number of subjects: 2706

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg
Number of subjects: 2706

Group type: EXPERIMENTAL
Intervention: Tertatolol
Number of subjects: 2706
Study: 3960619

Group type: EXPERIMENTAL
Intervention: Whey‐predominant, 50% medium chain triglyceride formula with 12.5 mg/L of zinc and 2.1 mg/L of copper
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whey‐predominant, 50% medium chain triglyceride formula with 12.5 mg/L of zinc and 0.9 mg/L of copper
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups received 12.5 mg/L of zinc
Number of subjects: 10
Study: 30339465

Group type: EXPERIMENTAL
Intervention: Composite Physical Activity Score (combination of reported and accelerometer-derived PA data)
Number of subjects: 3549

Group type: COMPARATOR
Intervention: Self-report only
Number of subjects: 3549

Group type: COMPARATOR
Intervention: Accelerometer only
Number of subjects: 3549

Group type: EXPERIMENTAL
Intervention: Self-report plus accelerometer
Number of subjects: 3549

Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 3549
Study: 27403058

Group type: EXPERIMENTAL
Intervention: Ozone gas (O3) applied for 12 seconds
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline solution used for irrigation
Number of subjects: 30
Study: 24691112

Group type: EXPERIMENTAL
Intervention: Genetic testing scenario
Number of subjects: 257

Group type: COMPARATOR
Intervention: Standard blood testing scenario
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Genetic testing scenario with higher genetic literacy
Number of subjects: 257
Study: 20678906

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 21105483

Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (0.35 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous morphine (0.25 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group E (Intravenous)
Number of subjects: 50
Study: 18681202

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy and radiotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy
Number of subjects: 63
Study: 15938592

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (250 microg subcutaneous) with a slow, four-stage, 4-week titration
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (250 microg subcutaneous) with a rapid, two-stage, 2-week titration
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 12933390

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus clonidine 1 micro g/mL
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 34
Study: 10739849

Group type: EXPERIMENTAL
Intervention: Elevated maternal total homocysteine concentrations (fasting >18.3 micromol/l and/or 6 h after methionine load >61.5 micromol/l)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Single chorionic vascular elements in women with elevated total homocysteine concentrations
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fasting total homocysteine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal total homocysteine concentrations
Number of subjects: 19
Study: 9014601

Group type: EXPERIMENTAL
Intervention: Epogam evening primrose oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study: 1574915

Group type: EXPERIMENTAL
Intervention: Combined immunization with purified Vero cell rabies vaccine and Typhim Vi
Number of subjects: 104

Group type: COMPARATOR
Intervention: Purified Vero cell rabies vaccine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Typhim Vi
Number of subjects: 104
Study: 6397973

Group type: EXPERIMENTAL
Intervention: 5 mg amphetamine sulfate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 7.5 mg amphetamine sulfate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 25 mg ephedrine hydrochloride
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 50 mg ephedrine hydrochloride
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Active drug (combined results of amphetamines and ephedrine)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29147810

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate intravaginal ring
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study: 28371401

Group type: EXPERIMENTAL
Intervention: AcrySof IQ® SN60WF
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tecnis® ZCB00
Number of subjects: 50
Study: 25415933

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 23137180

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with MPA
Number of subjects: 629

Group type: COMPARATOR
Intervention: Tacrolimus (Tac) with MPA
Number of subjects: 629
Study: 21652780

Group type: EXPERIMENTAL
Intervention: Brief Education and Counseling Intervention
Number of subjects: 389
Study: 18797683

Group type: EXPERIMENTAL
Intervention: Perfusion technique
Number of subjects: 39

Group type: COMPARATOR
Intervention: Balloon technique
Number of subjects: 39
Study: 17134627

Group type: EXPERIMENTAL
Intervention: GIK infusion (30% glucose, 50 IU of insulin, 80 mEq of potassium chloride infused at 1.5 ml/kg/hour over 24 hours)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 73
Study: 12694779

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 10971306

Group type: EXPERIMENTAL
Intervention: S-heparin (50 IU kg(‐1) via i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LMW heparin (50 IU kg(‐1) via i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: S-heparin (via s.c. injection)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LMW heparin (via s.c. injection)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline via i.v. injection)
Number of subjects: 18
Study: 8607575

Group type: EXPERIMENTAL
Intervention: PGE(1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study: 1451221

Group type: EXPERIMENTAL
Intervention: Nicardipine infusion (0.5‐2.0 micrograms.kg‐1 x min‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hANP infusion (0.05‐0.2 microgram.kg‐1 x min‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enflurane (increased concentration)
Number of subjects: 0
Study: 3967529

Group type: EXPERIMENTAL
Intervention: Total Body Weight (TBW)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ideal Body Weight (IBW)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Adjusted Body Weight (ABW)
Number of subjects: 54
Study: 29452929

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Iontophoresis
Number of subjects: 37

Group type: COMPARATOR
Intervention: Phonophoresis
Number of subjects: 37
Study: 29058358

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 or 2 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 27305830

Group type: EXPERIMENTAL
Intervention: Medication continuation (quetiapine 400 mg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Medication discontinuation (placebo)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 102
Study: 25077511

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 160

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 160
Study: 22311903

Group type: EXPERIMENTAL
Intervention: Combination of yohimbine (5.4 mg) and atomoxetine (18.0 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Yohimbine (5.4 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Atomoxetine (18.0 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 20102071

Group type: EXPERIMENTAL
Intervention: Subjects with glasses
Number of subjects: 54

Group type: COMPARATOR
Intervention: Subjects without glasses
Number of subjects: 54
Study: 17728707

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 2103

Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 2103
Study: 15215661

Group type: EXPERIMENTAL
Intervention: Toothbrushing instruction with re-instruction and reminder messages (Experimental Group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No follow-up intervention (Control Group)
Number of subjects: 26
Study: 12218962

Group type: EXPERIMENTAL
Intervention: Heterogeneous plaque (group A)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Homogeneous plaque (group B)
Number of subjects: 391
Study: 9846921

Group type: EXPERIMENTAL
Intervention: Doxapram (0.5 mg kg(‐1)h(‐1)) in combination with caffeine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9175807

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (atenolol or placebo)
Number of subjects: 32
Study: 2030246

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 6103707

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.5 mg oral
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.0 mg oral
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2.0 mg oral
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Flunitrazepam i.m. administration
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (all doses)
Number of subjects: 3
Study: 31826024

Group type: EXPERIMENTAL
Intervention: Integration of 'Movie Models' video intervention within six Feel4Diabetes counselling sessions.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 126
Study: 27869661

Group type: EXPERIMENTAL
Intervention: LAB⁴ANTI (30 billion CFU·day‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LAB⁴ (matched pro/prebiotic)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LAB⁴ANTI and LAB⁴
Number of subjects: 30
Study: 23375074

Group type: EXPERIMENTAL
Intervention: Iodised salt (IS) in cooking and at the table
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 200 μg potassium iodide (KI)/d
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 300 μg potassium iodide (KI)/d
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 131
Study: 20549511

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 40 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Misoprostol 40 mg vaginally
Number of subjects: 40
Study: 19801226

Group type: EXPERIMENTAL
Intervention: Greater palatine nerve block
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High tuberosity nerve block
Number of subjects: 40
Study: 16986383

Group type: EXPERIMENTAL
Intervention: Heparin (unfractionated or low-molecular-weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calf compression methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current methods of venous thromboprophylaxis
Number of subjects: 0
Study: 15717699

Group type: EXPERIMENTAL
Intervention: Needle-through-needle (NTN) technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Double-space technique
Number of subjects: 200
Study: 11707786

Group type: EXPERIMENTAL
Intervention: Paravenous approach using 5 mL mepivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blind subcutaneous injection using 5 mL mepivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paravenous approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blind subcutaneous injection
Number of subjects: 20
Study: 9172850

Group type: EXPERIMENTAL
Intervention: Immediate backrub after turning to the left side
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Delayed backrub after turning to the left side
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Turning to the left side
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Turning and immediate backrub
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Turning and delayed backrub
Number of subjects: 57
Study: 8147063

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 0
Study: 3533129

Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily
Number of subjects: 12
Study: 29955032

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 48
Study: 27380464

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2049
Study: 24938492

Group type: EXPERIMENTAL
Intervention: Patient-Led Assessment for Network Support (PLANS) intervention
Number of subjects: 20
Study: 22810739

Group type: EXPERIMENTAL
Intervention: Adaptol
Number of subjects: 75
Study: 20970090

Group type: EXPERIMENTAL
Intervention: Web-based substance use prevention program (9 sessions)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Test-only control arm
Number of subjects: 108
Study: 18829215

Group type: EXPERIMENTAL
Intervention: Corridor-based functional performance measures (6-minute walk, walking velocity over four meters at usual and fastest pace, SPPB)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Treadmill walking measures
Number of subjects: 156
Study: 15871020

Group type: EXPERIMENTAL
Intervention: Retinal Thickness Analyzer (RTA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inter-examiner analysis for RTA and OCT
Number of subjects: 22
Study: 12381090

Group type: EXPERIMENTAL
Intervention: Nicorandil (1.5 microg x kg(‐1) min(‐1))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nitroglycerin (0.5 microg x kg(‐1) min(‐1))
Number of subjects: 22
Study: 10480632

Group type: EXPERIMENTAL
Intervention: Nevirapine (50 microM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nevirapine treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nevirapine treatment after 1 week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis
Number of subjects: 30
Study: 8665548

Group type: EXPERIMENTAL
Intervention: Selegiline (5 mg b.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20